Employees department of Public Health



L.E. Coffeng MD PhD - click to enlarge
L.E. Coffeng MD PhD
Assistant Professor
Biography Research Interests Projects Publications Working papers Memberships Contact

    1.    Coffeng LE, Bakker R, Montresor A, et al. Feasibility of controlling hookworm infection through preventive chemotherapy: a simulation study using the individual-based WORMSIM modelling framework. Parasit Vectors. 2015;8(1):541. http://dx.doi.org/10.1186/s13071-015-1151-4. Impact factor 3.430 (S).

     

    2.    Stolk WA, Walker M, Coffeng LE, et al. Required duration of mass ivermectin treatment for onchocerciasis elimination in Africa: a comparative modelling analysis. Parasit Vectors. 2015;8(1):552. http://dx.doi.org/10.1186/s13071-015-1159-9. Impact factor 3.430 (S).

     

    3.    Krotneva SP, Coffeng LE, Noma M, et al. African Program for Onchocerciasis Control 1995-2010: Impact of Annual Ivermectin Mass Treatment on Off-Target Infectious Diseases. PLoS Negl Trop Dis. 2015;9(9):e0004051. http://dx.doi.org/10.1371/journal.pntd.0004051. Impact factor 4.446 (S).

     

    4.    GBD 2013 DALYs and HALE Collaborators.* Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet. 2015 (Epub ahead of print). http://dx.doi.org/10.1016/S0140-6736(15)61340-X. Impact factor 45.217 (S). *Member of GBD 2013 core team at Institute for Health Metrics and Evaluation, Seattle, WA, USA.

     

    5.    Goff KL, Karimkhani C, Boyers LN, …, Coffeng LE, et al. The global burden of psoriatic skin disease. Br J Dermatol. 2015;172(6):1665-8. http://dx.doi.org/10.1111/bjd.13715. Impact factor 4.275.

     

    6.    Coffeng LE, Stolk WA, Hoerauf A, Habbema D, Bakker R, Hopkins AD, de Vlas SJ. Elimination of African onchocerciasis: modeling the impact of increasing the frequency of ivermectin mass treatment. PLoS ONE 2014;9(12):e115886. http://dx.plos.org/10.1371/journal.pone.0115886. Impact factor 3.234 (S).

     

    7.    GBD 2013 Mortality and Causes of Death Collaborators.* Global, regional, and national mortality from 240 causes of death, 1990 and 2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117-71. http://dx.doi.org/10.1016/S0140-6736(14)61682-2. Impact factor 45.217 (S). *Member of GBD 2013 core team at Institute for Health Metrics and Evaluation, Seattle, WA, USA.

     

    8.    Coffeng LE. The health impact of onchocerciasis control in Africa [De gezondheidseffecten van onchocerciasis-bestrijding in Afrika]. Tijdschr Inf 2014;9:188-191. No impact factor available (S).

     

    9.    Karimkhani C, Boyers LN, Naghavi M, Coffeng LE, et al. The global burden of disease associated with alopecia areata. Br J Dermatol. 2015;172(5):1424-6. http://dx.doi.org/10.1111/bjd.13559. Impact factor 4.275.

     

    10.Vendrig JC, Coffeng LE, Fink-Gremmels J. Effects of orally administered galacto-oligosaccharides on immunological parameters in foals: a pilot study. BMC Vet Res. 2014;10:278. http://www.biomedcentral.com/1746-6148/10/278. Impact factor 1.777.

     

    11.Boyers LN, Karimkhani C, Naghavi M, …, Coffeng LE, et al. Global mortality from conditions with skin manifestations. J Am Acad Dermatol 2014;S0190-9622(14):01869-6. http://dx.doi.org/10.1016/j.jaad.2014.08.022. Impact factor 5.004.

     

    12.Schellens IM, Spits HB, Navis M, …, Coffeng LE, et al. Differential characteristics of cytotoxic T lymphocytes restricted by protective HLA alleles B*27 and B*57 in HIV-1 infection. J Acquir Immune Defic Syndr. 2014;67(3):236-45. http://dx.doi.org/10.1097/QAI.0000000000000324. Impact factor 4.556.

     

    13.Hotez PJ, Alvarado M, Basañez M-G, …, Coffeng LE, …, et al. The Global Burden of Disease Study 2010: interpretation and implications for the neglected tropical diseases. PLoS Negl Trop Dis. 2014;8(7):e2865. http://dx.doi.org/10.1371/journal.pntd.0002865. Impact factor 4.446 (S).

     

    14.Karimkhani C, Boyers LN, Margolis DJ, …, Coffeng LE, et al. Comparing cutaneous research funded by the National Institute for Arthritis and Musculoskeletal and Skin Diseases with 2010 Global Burden of Disease results. PLoS One. 2014 8;9(7):e102122. http://dx.doi.org/10.1371/journal.pone.0102122. Impact factor 3.234.

     

    15.Coffeng LE, Stolk WA, Zouré HG, et al. African Programme for Onchocerciasis Control 1995-2015: updated health impact estimates based on new disability weights. PLoS Negl Trop Dis. 2014;8(6):e2759. http://dx.doi.org/10.1371/journal.pntd.0002759. Impact factor 4.446 (S).

     

    16.Vendrig JC, Coffeng LE, Fink-Gremmels J. In vitro evaluation of defined oligosaccharide fractions in an equine model of inflammation. BMC Vet Res. 2013;9(1):147. http://dx.doi.org/10.1186/1746-6148-9-147. Impact factor 1.743.

     

    17.Vendrig JC, Coffeng LE, Fink-Gremmels J. Effects of separate and concomitant TLR-2 and TLR-4 activation in peripheral blood mononuclear cells of newborn and adult horses. PLoS ONE. 2013;8(6):e66897. http://dx.doi.org/10.1371/journal.pone.0066897. Impact factor 4.015.

     

    18.Coffeng LE, Pion SDS, O’Hanlon S, et al. Onchocerciasis: the pre-control association between prevalence of palpable nodules and skin microfilariae. PLoS Negl Trop Dis. 2013;7(4):e2168. http://dx.doi.org/10.1371/journal.pntd.0002168. Impact factor 4.489 (S).

     

    19.Vendrig JC, Coffeng LE, Fink-Gremmels J. Equine colostral carbohydrates reduce the lipopolysaccharide-induced inflammatory response in equine peripheral blood mononuclear cells. Equine Vet J Suppl. 2012;(43):68-72. http://dx.doi.org/10.1111/j.2042-3306.2012.00680. Impact factor 2.286.

     

    20.Coffeng LE, Stolk WA, Zouré HGM, et al. African Programme for Onchocerciasis Control 1995-2015: model-estimated health impact and cost.PLoS Negl Trop Dis. 2013;7(1):e2032. http://dx.doi.org/10.1371/journal.pntd.0002032. Impact factor 4.489 (S).

     

    21.Murray CJL, Vos T, Lozano R, …, Coffeng LE, …, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2197-223. http://dx.doi.org/10.1016/S0140-6736(12)61689-4. Impact factor 39.060 (S).

     

    22.Vos T, Flaxman AD, Naghavi M, …, Coffeng LE, …, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163-96. http://dx.doi.org/10.1016/S0140-6736(12)61729-2. Impact factor 39.060 (S).

     

    23.Lozano R, Naghavi M, Foreman K, …, Coffeng LE, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095-128. http://dx.doi.org/10.1016/S0140-6736(12)61728-0. Impact factor 39.060 (S).

     

    24.Coffeng LE, Fobi G, Ozoh G, et al. Concurrence of dermatological and ophthalmological morbidity in onchocerciasis. TRSTMH. 2012;106(4):243-251. http://dx.doi.org/10.1016/j.trstmh.2011.12.006. Impact factor 1.823 (S).

     

    25.Coffeng LE, Visscher AJE, ten Cate ThJ. Early clinical experiences affect career preference in male but not in female students. Med Teach. 2009; 31(7):e323-6. http://dx.doi.org/10.1080/01421590802650084. Impact factor 1.333.


    26.Ter Wolbeek M, van Doornen LJ, Coffeng LE, et al. Cortisol and severe fatigue: a longitudinal study in adolescent girls. Psychoneuroendocrinology. 2007 Feb;32(2):171-82. http://dx.doi.org/10.1016/j.psyneuen.2006.12.003. Impact factor 4.422.